prikaz prve stranice dokumenta Clinical relevance of natural killer cells in breast cancer
  Download
PDF 2.74 MB
Scientific paper - Review paper
Clinical relevance of natural killer cells in breast cancer
Medicina Fluminensis, 58 (2022), 2; 113-120. https://doi.org/10.21860/medflum2022_275128
Gulić, Tamara; Grebić, Damir; Starčević, Alma; Avirović, Manuela; Valković Zujić, Petra; Veljković Vujaklija, Danijela; Blagojević Zagorac, Gordana

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Gulić, T., Grebić, D., Starčević, A., Avirović, M., Valković Zujić, P., Veljković Vujaklija, D. & Blagojević Zagorac, G. (2022). Clinical relevance of natural killer cells in breast cancer. Medicina Fluminensis, 58. (2), 113-120. doi: 10.21860/medflum2022_275128

Gulić, Tamara, et al. "Clinical relevance of natural killer cells in breast cancer." Medicina Fluminensis, vol. 58, no. 2, 2022, pp. 113-120. https://doi.org/10.21860/medflum2022_275128

Gulić, Tamara, Damir Grebić, Alma Starčević, Manuela Avirović, Petra Valković Zujić, Danijela Veljković Vujaklija and Gordana Blagojević Zagorac. "Clinical relevance of natural killer cells in breast cancer." Medicina Fluminensis 58, no. 2 (2022): 113-120. https://doi.org/10.21860/medflum2022_275128

Gulić, T., et al. (2022) 'Clinical relevance of natural killer cells in breast cancer', Medicina Fluminensis, 58(2), pp. 113-120. doi: 10.21860/medflum2022_275128

Gulić T, Grebić D, Starčević A, Avirović M, Valković Zujić P, Veljković Vujaklija D, and sur.. Clinical relevance of natural killer cells in breast cancer. Medicina Fluminensis [Internet]. 2022 [cited 2024 November 08];58(2):113-120. doi: 10.21860/medflum2022_275128

T. Gulić, et al., "Clinical relevance of natural killer cells in breast cancer", Medicina Fluminensis, vol. 58, no. 2, pp. 113-120, 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:337098. [Accessed: 08 November 2024]

Metadata
Title (english)Clinical relevance of natural killer cells in breast cancer
Title (croatian)Klinička važnost prirodnoubilačkih stanica u karcinomu dojke
AuthorTamara Gulić
AuthorDamir Grebić
AuthorAlma Starčević
AuthorManuela Avirović
AuthorPetra Valković Zujić
AuthorDanijela Veljković Vujaklija
AuthorGordana Blagojević Zagorac
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Radiology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract (english)
Abstract. Breast carcinoma is the most common malignant disease in the female and one of the leading causes of death among women worldwide. Chronic inflammation and immunosuppressive environment achieved by the interaction of tumour and infiltrating immune cells are the hallmarks of cancers, including breast cancer. Natural killer cells are one of innate immune cells in tumour bed that possess great antitumour potential due to their ability to kill tumour cells without prior sensitization. They also play an important role in priming of type I immune responses and are considered to be main source of Interferon-γ. Unfortunately, antitumour activity of natural killer cells is often suppressed by proinflammatory cytokines secreted in tumour microenvironment and suppression of NK cells activity often correlates with therapy response and general outcome of patient with breast carcinoma. Different types of breast cancer are associated with different subsets of natural killer cells that possess different immunoregulatory function. Identification of specific tumour associated natural killer cell subset endowed with different functional capabilities might help practitioners in therapy decisions, therapy response monitoring, as well as in predicting overall prognosis of breast cancer patients. The purpose of this review is to give an overview of natural killer cells and their subsets, their role in pathogenesis of breast cancer and to discuss NK cells as potential useful therapy and prognostic tool for breast carcinomas.
Abstract (croatian)
Sažetak. Karcinom dojke je maligna bolest u žena i jedan je od vodećih uzroka smrti žena širom svijeta. Kronična upala i imunosupresivni okoliš koji nastaje kao posljedica interakcije tumorskih stanica i infiltrirajućih imunoloških stanica obilježja su karcinoma, uključujući karcinom dojke. Prirodnoubilačke stanice (NK stanice) jedna su od subpopulacija urođenih imunoloških stanica u tumorskom sijelu, koje posjeduju antitumorski potencijal zbog svoje sposobnosti direktnog ubijanja tumorskih stanica bez prethodne senzibilizacije. Također, igraju važnu ulogu u pripremi imunološkog odgovora tipa 1 i smatraju se glavnim izvorom interferona-γ. Nažalost, antitumorska aktivnost NK stanica često je potisnuta proupalnim citokinima koji se izlučuju u tumorskom mikrookolišu, a supresija aktivnosti NK stanica obično korelira s terapijskim odgovorom i općim lošijim ishodom kod bolesnica s karcinomom dojke. Surogati molekularnih podtipova karcinoma dojke povezani su s različitim subpopulacijama NK stanica, koje posjeduju različite imunoregulacijske funkcije. Identifikacija specifične subpopulacije NK stanica pridruženih s tumorom, koje posjeduju različite imunološke funkcije, može pomoći liječnicima u donošenju odluka o terapiji, praćenju terapijskog odgovora, kao i u predviđanju ukupne prognoze pacijenata s karcinomom dojke. Svrha je ovog preglednog članka istaknuti važnost NK stanica i njihovih subpopulacija u patogenezi karcinoma dojke te diskutirati terapijske i prognostičke mogućnosti korištenja NK stanica u osoba oboljelih od karcinoma dojke.
Keywords (english)
Keywords (croatian)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMedicina Fluminensis
Numberingvol. 58, no. 2, pp. 113-120
p-ISSN1847-6864
e-ISSN1848-820X
DOIhttps://doi.org/10.21860/medflum2022_275128
URN:NBNurn:nbn:hr:184:337098
Publication2022
Document URLhttps://hrcak.srce.hr/275128
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-06-13 12:59:14